Eversept Partners LP Takes Position in Esperion Therapeutics, Inc. $ESPR

Eversept Partners LP bought a new stake in Esperion Therapeutics, Inc. (NASDAQ:ESPR) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 3,851,133 shares of the biopharmaceutical company’s stock, valued at approximately $14,249,000. Eversept Partners LP owned about 1.61% of Esperion Therapeutics as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the business. ACT Capital Management LLC acquired a new stake in shares of Esperion Therapeutics in the fourth quarter valued at about $176,000. Schonfeld Strategic Advisors LLC acquired a new stake in shares of Esperion Therapeutics in the fourth quarter valued at about $278,000. Burkehill Global Management LP acquired a new stake in shares of Esperion Therapeutics in the fourth quarter valued at about $1,480,000. AQR Capital Management LLC raised its position in shares of Esperion Therapeutics by 2.0% in the fourth quarter. AQR Capital Management LLC now owns 290,514 shares of the biopharmaceutical company’s stock valued at $1,075,000 after buying an additional 5,608 shares during the last quarter. Finally, Abel Hall LLC raised its position in shares of Esperion Therapeutics by 138.4% in the fourth quarter. Abel Hall LLC now owns 28,943 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 16,801 shares during the last quarter. 47.39% of the stock is currently owned by institutional investors and hedge funds.

Esperion Therapeutics Trading Up 0.3%

Shares of ESPR opened at $3.17 on Thursday. The firm has a market capitalization of $816.88 million, a P/E ratio of -52.83, a P/E/G ratio of 2.57 and a beta of 1.07. The firm has a 50-day moving average price of $2.75 and a 200 day moving average price of $3.12. Esperion Therapeutics, Inc. has a 12-month low of $0.95 and a 12-month high of $4.18.

Esperion Therapeutics (NASDAQ:ESPR) last announced its earnings results on Friday, May 8th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.08). The company had revenue of $80.10 million for the quarter, compared to analysts’ expectations of $84.52 million. Esperion Therapeutics had a negative return on equity of 0.14% and a net margin of 0.12%.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the stock. Needham & Company LLC lowered shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, May 4th. Cantor Fitzgerald lowered shares of Esperion Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, May 1st. Citizens Jmp lowered shares of Esperion Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, May 1st. HC Wainwright lowered shares of Esperion Therapeutics from a “buy” rating to a “neutral” rating and set a $3.16 price objective for the company. in a report on Friday, May 1st. Finally, Jefferies Financial Group lowered shares of Esperion Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, May 1st. One investment analyst has rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Esperion Therapeutics currently has an average rating of “Hold” and an average target price of $5.54.

About Esperion Therapeutics

Esperion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company’s research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.

The company’s lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S.